Press release

In 2025, Yazen's revenue surged 87% to nearly €29.4 million, with gross profits doubling to €16.5 million. Now treating over 37,000 active patients across seven countries, the company is eyeing further expansion into two more markets in 2026. Despite an EBITDA of –€5.7 million due to heavy growth investment, Yazen remains a leader in European obesity care.

Yazen presents an oral scientific abstract at the Nordic Obesity Meeting (NOM26), highlighting high-volume patient–caregiver interactions in a fully digital obesity care model.

Yazen wins “Weight Loss Treatment of the Year 2025 award” for its innovative, evidence-based care helping over 47,000 patients achieve sustainable weight loss.

Yazen named the fastest-growing startup in the Nordics and Benelux in the Sifted 100 Leaderboard

Yazen partners with Withings to go beyond BMI for better health insights.

Yazen expands in Scandinavia through the acquisition of Danish company Medstart, which is established in Denmark and Norway. Together, they enhance care for people with obesity.

Yazen Health has successfully closed an oversubscribed €19.5 million series A funding round to fuel its international expansion. This investment enables Yazen to enhance its pioneering obesity treatment model, combining modern weight loss medication with comprehensive lifestyle support.

The obesity epidemic is one of the greatest health challenges of our time. Globally, it is estimated that 1.9 billion people will suffer from morbid obesity by 2035, which represents one in four adults. Among children, obesity is expected to increase by 100 percent between 2020 and 2035. The cost to society is projected to be 4 trillion dollars.

Martin Carlsson participates in "Where next for digital health? A roundtable debate hosted by Health Tech World

Patients at the digital healthcare provider Yazen have now collectively shed 60 tonnes